Carl Zeiss Meditec continues its profitable growth in first six months of financial year 2011/2012
(Thomson Reuters ONE) -
Carl Zeiss Meditec AG /
Carl Zeiss Meditec continues its profitable growth in first six months of
financial year 2011/2012
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Revenue 14.8 percent higher than previous year - EBIT margin grows to 14.1
percent
JENA/Germany, 15 May 2012
Medical technology provider Carl Zeiss Meditec generated growth of 14.8 percent
in the first six months of financial year 2011/2012. The company posted revenue
of EUR 431.8 million - EUR 56 million more than for the same period of the
previous year (EUR 376.0 million). Once again, Carl Zeiss Meditec AG improved
its profitability, increasing its earnings before interest and tax (EBIT) by 19
percent to EUR 61.1 million (previous year: EUR 51.3 million). The EBIT margin
increased to 14.1 percent (previous year: 13.6 percent).
"I am particularly delighted that we achieved very profitable growth," says Dr.
Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. "The half-year result
is an endorsement of our strategy to strengthen our broad business portfolio
with innovations and to grow on a global scale."
Key figures at a glance
The largest contribution to total revenue came from the Microsurgery business
unit, with growth of 23.9 percent. This increase in revenue is due in particular
to the new products launched last year. Radiation therapy sales also showed
continuing growth.
The Surgical Ophthalmology business unit benefited from the strong demand for
intraocular lenses for minimally invasive cataract surgery. This strategic
business unit (SBU) grew by 14.8 percent.
The Ophthalmic Systems SBU grew by 6.6 percent. In particular the new ReLEx(®)
smile procedure for refractive laser surgery, launched in 2011, contributed to
this growth.
In terms of the reporting regions, the stable trend in the Asia/Pacific region
continued with growth of 13.3 percent. This region continues to hold the
greatest growth potential. A perceptible recovery in Europe and America also led
to encouraging growth in these two regions. "Nevertheless, this was an unusual
quarter characterized by backlog effects," explains Monz. Revenue in the EMEA
region grew by 14.9 percent. Both the consolidation of the business operations
acquired from IMEX in Spain and the strong demand in Eastern Europe are
continuing to have a positive effect. Revenue in the Americas region increased
by 16.2 percent. The US continued to perform well, while South America once
again achieved double-digit growth.
Confident about the future
Carl Zeiss Meditec is forecasting further growth in the second half of the
current financial year, assuming that the economic climate continues to
stabilize. However, this growth will not be quite as significant as in the first
six months, partly for seasonal reasons.
"Our revenue target for financial year 2011/2012 as a whole is EUR 830 to
EUR 860 million. This would mean year-on-year growth of between 9.4 and 13.3
percent," says Monz. "We are adhering to our target of achieving an EBIT margin
of 15 percent by 2015."
Revenue by strategic business unit
+----------------------+------------------+------------------+-----------------+
|Figures in ? '000 |6 Months 2010/2011|6 Months 2011/2012|Change from |
| | | |previous year |
+----------------------+------------------+------------------+-----------------+
|Ophthalmic Systems |173,367 |184,781 |6.6% |
+----------------------+------------------+------------------+-----------------+
|Surgical Ophthalmology|45,256 |51,942 |14.8% |
+----------------------+------------------+------------------+-----------------+
|Microsurgery |157,421 |195,075 |23.9% |
+----------------------+------------------+------------------+-----------------+
Revenue by region
+-------------------+------------------+------------------+--------------------+
|Figures in ? '000 |6 Months 2010/2011|6 Months 2011/2012|Change from previous|
| | | |year |
+-------------------+------------------+------------------+--------------------+
|EMEA |129,996 |149,423 |14.9% |
+-------------------+------------------+------------------+--------------------+
|Americas |124,024 |144,083 |16.2% |
+-------------------+------------------+------------------+--------------------+
|Asia/Pacific region|122,024 |138,292 |13.3% |
+-------------------+------------------+------------------+--------------------+
Press contacts:
Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss Meditec AG
Phone03641 220-331, E-Mail: press(at)meditec.zeiss.com
Investors contact:
Henriette Meyer, Director Investor Relations, Carl Zeiss Meditec AG
Phone 03641 220-106, E-Mail: investors(at)meditec.zeiss.com
www.meditec.zeiss.de/presse
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Carl Zeiss Meditec AG via Thomson Reuters ONE
[HUG#1612196]
Unternehmensinformation / Kurzprofil:
Datum: 15.05.2012 - 07:00 Uhr
Sprache: Deutsch
News-ID 146328
Anzahl Zeichen: 6282
contact information:
Town:
Jena
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Carl Zeiss Meditec continues its profitable growth in first six months of financial year 2011/2012"
steht unter der journalistisch-redaktionellen Verantwortung von
Carl Zeiss Meditec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
